Justin Gover

Justin Gover, Chief Executive Officer of Greenwich Biosciences, discusses the FDA's planned review of Epidiolex, a formulation of cannabidiol, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.


The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel .

Next Article:

Related Articles